OFF-X (Translational Safety/Toxicology), and its Cortellis Drug Discovery Intelligence with BioMarkers Module software application license subscription

Background
The National Institute on Drug Abuse (NIDA), Contracts Management Branch – Red (CMB) on behalf of the NIDA, Intramural Research Program (NIDA-IRP) intends to award a sole source contract to Clarivate Analytics for a software subscription and user license to the OFF-X (Translational Safety/Toxicology), and Cortellis Drug Discovery Intelligence software application with BioMarkers Module from Clarivate Analytics LLC without providing for full or open competition. The Office of Translational Initiatives and Program Innovations (OTIPI) is seeking to renew its user license and subscription to the Clarivate Analytics OFF-X (Translational Safety/Toxicology), and Cortellis Drug Discovery Intelligence software application. OTIPI has used the Drug Research Advisor and Cortellis Drug Discovery Intelligence software application software since 2014 and completed various projects related to the SBIR/STTR Business Program and Translational Initiatives. The database is used to identify Pharmaceutical companies interested in investing in NIDA funded SBIR/STTR companies, identify promising drugs, formulations, and models which are not currently used in the substance abuse ecosystem, and identify the history of the research and development related to the specific biological target.

The estimated period of performance shall be 04/1/2024 through 03/31/2025.

Work Details
The database is used to identify Pharmaceutical companies interested in investing in NIDA funded SBIR/STTR companies, identify promising drugs, formulations, and models which are not currently used in the substance abuse ecosystem, and identify the history of the research and development related to the specific biological target.

Period of Performance
04/1/2024 through 03/31/2025